StockData

Kiora Pharmaceuticals vs Kazia Therapeutics

KPRX and KZIA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KPRX and KZIA compare

Kiora Pharmaceuticals scores higher on the StockData Score (7 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKPRXKZIA
Size and price
Market cap$4.3M–
Share price$0.982$5.60
Change, 1 year−55.3%−23.2%
Change, 5 years−99.8%−98.9%
Beta (5Y)1.594.01
Employees3,50014
StockData Score
Total score7 (better)1
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/B0.3×–
FCF yield−198%–
Growth
Revenue growth (TTM)–−98.2%
Profitability
Net margin–−49291%
Return on equity−56.4%–
Return on invested capital−1374%–
Financial health
Debt / equity0.00–
Current ratio8.97 (better)2.87
Altman Z-score−9.80–
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions25.0%0.45%
Held by insiders3.0%0.29%
Superinvestors holding–1

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.